This work, together with our recent reported PDL1-Vax, lays out a new strategy to overcome the problem of immune tolerance, and promotes the development of drugs targeting MSLN as the relevant antigen, which have theoretical and application values in the development of tumor immunotherapy in human. Here, CD274 is linked to neoplasm.